RxDoctor Payments Data

Thomas Etherton, NP

Primary Care · Olympia, WANPI 1912547365

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 38.8% of the total. 2025 is the largest year on record at $478, more than ten times the $16 reported in 2021.

$1,339in general payments, 2019–2025

Across 65 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$520
  • Novo Nordisk$179
  • Exact Sciences$160
  • Johnson & Johnson$83
  • Medtronic$68
  • Organon$51
  • plus $278 from 11 others

What the payments were for

  • Food & beverage$1,339100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,339 in reported general payments places this provider in the 80th percentile of 94 primary care providers in Washington.

See all primary care providers in Washington

Medicare billing

Part B allowed, 2024
$2,225
Medicare patients
12
Services billed
26

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$13,596
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,642
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl20$4,459
Albuterol Sulfate HfaAlbuterol Sulfate27$381
Pantoprazole Sodium30$290
Divalproex Sodium ErDivalproex Sodium11$251
Trazodone Hcl63$234
Duloxetine Hcl21$204
Gabapentin30$187
Zolpidem Tartrate25$173
Atorvastatin Calcium21$147
Levothyroxine Sodium21$132
Lisinopril29$131
Nystatin11$125
Tramadol Hcl25$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$179$13,59615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 94 primary care providers in Washington.

Other primary care in Olympia

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →